Immunotherapy plus standard care for pancreatic cancer with fluid buildup
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new immunotherapy medicine (adebrelimab) added to standard care for people with pancreatic cancer that has caused fluid buildup in the belly or around the lungs. The goal is to see if this combination can help control the cancer and reduce the fluid buildup.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with pancreatic cancer.
- You have a significant buildup of fluid in your belly or around your lungs that needs medical drainage.
- You are able to carry out daily activities (even if you need bed rest for part of the day).
- Your blood counts and liver/kidney function are within safe ranges.
- You cannot have had immunotherapy given directly into your chest or belly before.
- You must not have uncontrolled autoimmune disease, active infections, or other major cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
This trial tests a new medicine (IBI363) combined with chemotherapy for people with advanced pancreatic cancer that has grown after their first treatment. The goal is to see if this combination can help shrink or control the cancer longer.
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Hear when a new Pancreatic Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.